Targeted therapeutics for severe refractory asthma: monoclonal antibodies.

Grainge, Christopher L; Maltby, Steven; Gibson, Peter G; Wark, Peter A B; McDonald, Vanessa M

Grainge, Christopher L; Maltby, Steven; Gibson, Peter G; Wark, Peter A B; McDonald, Vanessa M.

Afiliação

Grainge CL; a Centre of Excellence in Severe Asthma, Hunter Medical Research Institute and Priority Research Centre for Healthy Lungs , The University of Newcastle , Newcastle , Australia.
Maltby S; b Department of Respiratory and Sleep Medicine , John Hunter Hospital , Newcastle , Australia.
Gibson PG; a Centre of Excellence in Severe Asthma, Hunter Medical Research Institute and Priority Research Centre for Healthy Lungs , The University of Newcastle , Newcastle , Australia.
Wark PA; a Centre of Excellence in Severe Asthma, Hunter Medical Research Institute and Priority Research Centre for Healthy Lungs , The University of Newcastle , Newcastle , Australia.
McDonald VM; b Department of Respiratory and Sleep Medicine , John Hunter Hospital , Newcastle , Australia.

Expert Rev Clin Pharmacol ; 9(7): 927-41, 2016 Jul.

Article em En | MEDLINE | ID: mdl-27018798

Assuntos

Antiasmáticos/uso terapêutico; Anticorpos Monoclonais/uso terapêutico; Asma/tratamento farmacológico; Animais; Antiasmáticos/farmacologia; Anticorpos Monoclonais/farmacologia; Asma/fisiopatologia; Humanos; Terapia de Alvo Molecular; Fenótipo; Autocuidado/métodos; Índice de Gravidade de Doença

Palavras-chave

Severe asthma; biomarker; monoclonal; multidimensional assessment; phenotype; targeted therapy; treatment-refractory asthma

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Asma / Antiasmáticos / Anticorpos Monoclonais Limite: Animals / Humans Idioma: En Revista: Expert Rev Clin Pharmacol Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Austrália

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google